<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04168502</url>
  </required_header>
  <id_info>
    <org_study_id>AML1819</org_study_id>
    <nct_id>NCT04168502</nct_id>
  </id_info>
  <brief_title>Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML</brief_title>
  <official_title>Phase 3 Study to Assess Gemtuzumab, in Combination With Standard Chemotherapy, on MRD Levels, and the Role of Glasdegib as a Post-transplant Maintenance, in Adult, 18-60 Years, With Previously Untreated de Novo Fav-interm Risk AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MRD driven study. Addition of gemtuzumab to conventional chemotherapy to reduce MRD of&#xD;
      patients with favorable/intermediate-risk AML. Post-consolidation assessment of MRD. Role of&#xD;
      a post-SCT maintenance with glasdegib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Setting up a multicenter, MRD (Minimal Residual Disease)-driven study that relies on addition&#xD;
      of gemtuzumab ozogamicin to conventional chemotherapy to reduce the pre-transplant levels of&#xD;
      MRD of patients with favorable/intermediate-risk (according to ELN 2017) AML.&#xD;
      Post-consolidation assessment of MRD will be exploited to establish the final risk assignment&#xD;
      and to verify whether the delivery of a post remission therapy intensity (AuSCT, Autologous&#xD;
      Stem Cell Transplant, vs ASCT, Allogeneic Stem Cell Transplant) of which is MRD-driven will&#xD;
      improve the outcome in terms of anti-leukemic efficacy. Finally, the role of a post-SCT&#xD;
      maintenance with glasdegib will be explored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Activity of GO in combination with chemotherapy in terms of MRD negativity achievement</measure>
    <time_frame>2 months</time_frame>
    <description>Percentage of MRD negativity after consolidation in patients treated in induction and consolidation with GO</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Glasdegib maintenance vs clinical observation</measure>
    <time_frame>2,5 years</time_frame>
    <description>Disease Free Survival (DFS) in patients randomized to glasdegib maintenance or clinical observation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">414</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction:&#xD;
Gemtuzumab 3 mg/m2 day 1,4,7 Daunorubicin 60 mg/m2 day 1-3 Cytosine arabinoside 200 mg/m2 day 1-7&#xD;
Consolidation:&#xD;
Gemtuzumab 3 mg/m2 day 1 Daunorubicin 50 mg/m2 day 4-6 Cytosine arabinoside 500 mg/m2 twice a day, day 1-6&#xD;
Allogeneic transplantation or Autologous transplantation according to MRD level&#xD;
Maintenance with glasdegib 100 mg daily for one year or until toxicity/relapse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction:&#xD;
Gemtuzumab 3 mg/m2 day 1,4,7 Daunorubicin 60 mg/m2 day 1-3 Cytosine arabinoside 200 mg/m2 day 1-7&#xD;
Consolidation:&#xD;
Gemtuzumab 3 mg/m2 day 1 Daunorubicin 50 mg/m2 day 4-6 Cytosine arabinoside 500 mg/m2 twice a day, day 1-6&#xD;
Allogeneic transplantation or Autologous transplantation according to MRD level&#xD;
clinical observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glasdegib</intervention_name>
    <description>After randomization patients in both arms will be randomized to maintenance with glasdegib vs clinical observation</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemtuzumab Ozogamicin</intervention_name>
    <description>Both arms, before randomization, will receive induction and consolidation with Gemtuzumab ozogamicin, Daunorubicin and Cytarabine</description>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_label>Standard arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent according to ICH/EU/GCP and national/local laws&#xD;
&#xD;
          2. Patients aged between 18 and 60 years&#xD;
&#xD;
          3. Patients previously untreated for their AML by other chemotherapeutic agents (except&#xD;
             for no more than 7 days HU) or radiotherapy&#xD;
&#xD;
          4. Unequivocal diagnosis of de novo AML according to WHO diagnostic criteria (at least&#xD;
             20% blasts in the bone marrow), other than acute promyelocytic leukemia, documented by&#xD;
             bone marrow aspiration (or biopsy in case of dry tap) (not supervening after other&#xD;
             myeloproliferative disease or myelodysplastic syndromes of ≥ 6 months duration)&#xD;
&#xD;
          5. Patients with favorable-intermediate AML according to ELN 2017 (except for&#xD;
             FLT3-ITD/TKD positive AML)&#xD;
&#xD;
          6. WHO performance status 0-3&#xD;
&#xD;
          7. Adequate renal (serum creatinine ≤ 2 x the institutional ULN) and liver (total serum&#xD;
             bilirubin ≤ 2 x ULN; serum ALT and AST ≤ 2.5 x ULN) function, unless considered due to&#xD;
             organ leukemic involvement&#xD;
&#xD;
          8. Left Ventricular Ejection Fraction (LVEF) ≥ 50%, as determined by echocardiogram&#xD;
&#xD;
          9. Absence of severe concomitant neurological or psychiatric diseases and congestive&#xD;
             heart failure or active uncontrolled infection&#xD;
&#xD;
         10. Absence of any psychological, familial, sociological and geographical condition&#xD;
             potentially hampering compliance with the study protocol and the follow-up schedule.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients already treated for their AML by other chemotherapeutic agents (except for no&#xD;
             more than 7 days HU) or radiotherapy&#xD;
&#xD;
          2. Acute promyelocytic leukemia&#xD;
&#xD;
          3. Blast crisis of chronic myeloid leukemia&#xD;
&#xD;
          4. FLT3-ITD/TKD positive AML&#xD;
&#xD;
          5. AML supervening after other myeloproliferative disease ≥ 6 months duration&#xD;
&#xD;
          6. AML supervening after antecedent myelodysplastic syndromes&#xD;
&#xD;
          7. Therapy-related AML&#xD;
&#xD;
          8. Other active or progressive malignant diseases.&#xD;
&#xD;
          9. Inadequate renal or liver function (metabolic abnormalities &gt; 2-2.5 times the normal&#xD;
             upper limit)&#xD;
&#xD;
         10. Severe heart failure requiring diuretics&#xD;
&#xD;
         11. Ejection fraction &lt; 50%&#xD;
&#xD;
         12. Uncontrolled infections&#xD;
&#xD;
         13. Severe concomitant neurological or psychiatric diseases&#xD;
&#xD;
         14. Patients who are pregnant or adults of reproductive potential not employing an&#xD;
             effective method of birth control. Women of childbearing potential must have a&#xD;
             negative serum pregnancy test within 48 hours prior to administration of chemotherapy.&#xD;
             Post-menopausal women must be amenorrheic for at least 12 months to be considered of&#xD;
             non-childbearing potential. Male and female patients must agree to employ an effective&#xD;
             barrier method of birth control throughout the study and for at least 6 months&#xD;
             following discontinuation of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <phone>0670390528</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <phone>0670390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.O. - SS. Antonio e Biagio e Cesare Arrigo - SC Ematologia</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zallio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO &quot;San Giuseppe Moscati&quot; - UOC Ematologia con unità di trapianto</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Storti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Consorziale Policlinico &quot;Aldo Moro&quot; - UO Ematologia con trapianto</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carluccio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola - Malpighi - UOC Ematologia</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Nord &quot;Santa Maria Goretti&quot; - UOC Ematologia</name>
      <address>
        <city>Latina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cimino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - UO Ematologia</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Di Renzo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Tor Vergata- UOC Trapianto cellule staminali</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriano Venditti</last_name>
      <email>adriano.venditti@uniroma2.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>De-novo</keyword>
  <keyword>Favorable risk</keyword>
  <keyword>Intermediate risk</keyword>
  <keyword>Gemtuzumab ozogamicin</keyword>
  <keyword>Glasdegib</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

